The mechanisms of action of these therapies and the role of endogenous incretins are active areas of research, particularly considering the controversies surrounding agonism/antagonism of GIPR as potential treatments for obesity (11, 12). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.